Neulasta® Prefilled Syringe for Chemotherapy-Induced Neutropenia

Neulasta is a long-acting form of pegfilgrastim used to help prevent infection during chemotherapy. This page explains what it is, how it is used, and key safety points. It also shows how to review options and place your order with US delivery from Canada, including guidance for Neulasta prefilled syringe without insurance.

What Neulasta Is and How It Works

Neulasta® contains pegfilgrastim, a long-acting granulocyte colony-stimulating factor. It helps the body make more neutrophils, a type of white blood cell. Increasing neutrophils lowers the chance of febrile neutropenia in patients receiving myelosuppressive chemotherapy. The prefilled syringe includes an UltraSafe guard to support safer handling after injection.

Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

This medicine stimulates the bone marrow to produce neutrophils. It may shorten the time neutrophils are very low during a cycle. Most patients receive one injection per chemotherapy cycle as directed by a prescriber. The class effect can include bone pain; talk with a healthcare professional about suitable pain management if needed.

The device presentation aligns with pegfilgrastim labeling. Pegfilgrastim prefilled syringe UltraSafe Guard is a presentation used to support safety after dose administration.

Who It’s For

This treatment is used to reduce the incidence of infection, as manifested by febrile neutropenia, in adults receiving myelosuppressive chemotherapy associated with a clinically significant risk of severe neutropenia. It is not a substitute for antibiotics. It is not indicated for patients receiving chemotherapy regimens with minimal myelosuppression.

Patients with a history of serious allergic reactions to pegfilgrastim or filgrastim should avoid this product. Caution is advised in those with sickle cell disease, a history of splenic problems, or acute respiratory symptoms. Discuss individual risk with a prescriber before starting therapy.

For background on the condition and how clinicians assess risk, see Febrile Neutropenia and Neutropenia. Many patients receiving systemic cancer therapy also explore supportive care topics in our Cancer category.

Dosage and Usage

Follow the FDA-approved prescribing information. A typical adult schedule is one subcutaneous dose once per chemotherapy cycle. Administer approximately 24 hours after cytotoxic chemotherapy, and at least 14 days before the next cycle begins. Do not give within 24 hours before chemotherapy starts. Site rotation and aseptic technique help reduce local reactions.

Pegfilgrastim injection 6 mg is the standard adult dose when using the single-dose prefilled syringe. Pediatric dosing, when applicable, is weight-based as described in official labeling. Always confirm the timing for each regimen with the treating prescriber and the infusion team.

General administration reminders: allow the syringe to reach room temperature as directed on the label before use, inspect the solution visually for particulate matter and discoloration, and do not shake the syringe. If the solution is cloudy or discolored, do not use it.

Strengths and Forms

The product is typically supplied as a single-dose prefilled syringe with an UltraSafe needle guard. Many listings are the single 6 mg dose in 0.6 mL. Neulasta 6 mg/0.6 mL injection is the presentation most patients recognize. Availability can vary by pharmacy partner and jurisdiction.

Packaging often includes a protective carton to shield from light. The device is intended for subcutaneous use only. Some markets also offer an on-body injector version under related brand lines; this page focuses on the prefilled syringe with UltraSafe guard.

Missed Dose and Timing

If a scheduled dose is missed relative to the chemotherapy window, contact the prescribing clinic for guidance. Do not take extra doses to make up for a missed injection. The timing around chemotherapy is important to align with label recommendations. When in doubt, defer to the official label and the treating team on how to proceed for the current cycle.

Storage and Travel Basics

Store the prefilled syringe in a refrigerator as indicated on the label, protected from light in the original carton. Do not freeze. If the syringe has been inadvertently frozen, do not use it. Avoid shaking the syringe during handling and transport. When preparing for use, allow it to come to room temperature as directed on the package insert.

For travel, keep the syringe in the original packaging inside an insulated bag with cooler packs if needed, ensuring the device does not touch ice directly. Carry documentation such as the prescription label and a copy of the clinic instructions when passing security. Remember child-safety practices: keep medicines out of reach and sight in any setting.

When traveling across time zones during active chemotherapy, coordinate timing with the oncology team in advance. The clinic can confirm the safe window for administration relative to infusion schedules.

Pen Handling and Sharps Disposal

This product is a prefilled syringe. After injection, the UltraSafe guard is designed to cover the needle to reduce accidental needlesticks. Neulasta prefilled syringe UltraSafe needle guard describes the integrated safety feature.

Dispose of used syringes in a puncture-resistant sharps container. Do not recap the needle or throw syringes into household trash or recycling. Follow local regulations for sharps return through pharmacy programs or community drop sites. If a dose is not used, do not attempt to reinsert the needle into the cap; contact a pharmacy for safe disposal advice.

Benefits

This therapy can reduce the risk of febrile neutropenia in eligible patients receiving myelosuppressive chemotherapy. The long-acting profile means one injection per cycle for most adults, which simplifies scheduling. The device format helps support safer post-injection handling. Patients may feel more confident starting subsequent chemotherapy cycles on time when neutrophil counts recover as expected, though individual responses vary.

Side Effects and Safety

• Bone pain
• Pain in arms or legs
• Headache
• Injection site redness or discomfort
• Nausea

Serious risks can include splenic rupture, acute respiratory distress syndrome, serious allergic reactions, capillary leak syndrome, aortitis, and severe sickle cell crises in at-risk individuals. Report left upper abdominal or shoulder pain, breathing difficulty, rash, swelling, or signs of infection promptly. Very high white blood cell counts can occur. If used with insulin or sulfonylureas, hypoglycemia is not typical for this class, but overall illness may affect glucose control; coordinate management with the care team when relevant.

Drug Interactions and Cautions

Clinically significant drug-drug interactions are not commonly reported, but lithium may enhance neutrophil release; clinicians may monitor counts accordingly. Vaccination timing, particularly with live vaccines, should be discussed with the oncology team. Use caution in patients with preexisting splenic disorders, pulmonary compromise, or sickle cell disease. Hypersensitivity to components is a contraindication.

Always provide a complete medication list, including over-the-counter products and supplements, to the prescriber. The oncology team may adjust monitoring plans based on concomitant therapies and comorbid conditions.

What to Expect Over Time

Neutrophil counts typically rise after administration, which can reduce time spent with very low counts. Many patients experience bone pain early in the course; clinicians may suggest supportive options if appropriate. Expectations during each cycle depend on the chemotherapy regimen, baseline counts, and overall health. Consistent scheduling and adherence to the timing window help align results with the intended effect.

Keep track of cycle dates and planned injections on a calendar. If uncertainties arise regarding timing relative to infusion day, contact the clinic before making changes. Patients often feel more at ease when the plan is reviewed ahead of each cycle.

Compare With Alternatives

Several biologic options in this class may be considered if appropriate. Biosimilar pegfilgrastim products can be alternatives when a prescriber approves a substitution. For example, some patients may be candidates for Omlyclo Prefilled Syringe or may discuss Nypozi Prefilled Syringe with their clinician. Product selection depends on availability, the care plan, and jurisdictional substitution rules.

Pricing and Access

Canadian-sourced listings can help patients manage costs compared with some local options. If you are reviewing Neulasta prefilled syringe price, use the product page to see current pricing and available pack sizes. Our checkout supports card payment and pharmacy coordination with the prescribing clinic when required.

We provide US shipping from Canada with clear status updates. If you are looking for savings opportunities, see our seasonal updates on Promotions. For security, we maintain encrypted checkout across the site.

Availability and Substitutions

Supply can vary. If a specific presentation is unavailable, a prescriber may recommend a clinically appropriate alternative in the same class. Pharmacy teams follow local substitution rules and will confirm with the prescriber before dispensing a change. We do not guarantee stock timing; options shown reflect current partner inventory at the time of viewing.

Patient Suitability and Cost-Saving Tips

Candidates include adults receiving myelosuppressive chemotherapy where the anticipated risk of febrile neutropenia is clinically significant. It is not indicated for regimens with minimal myelosuppression. Patients with a history of serious hypersensitivity to filgrastim products should not use it. Those with sickle cell disease or splenic concerns require careful counseling.

To manage costs, consider multi-month planning aligned to chemotherapy cycles, if appropriate and allowed by your prescriber. Using a calendar for refills helps avoid last-minute changes. If you plan to travel during treatment, coordinate shipment timing and storage plans in advance. For education on related oncology therapies and care, see articles such as Ibrance Targeted Treatment, Leukeran Medication Guide, and Tasigna Uses Overview.

Questions to Ask Your Clinician

• Risk assessment: how high is my risk of febrile neutropenia on this regimen?
• Timing plan: when exactly should the injection occur relative to infusion day?
• Technique: who will administer, and what training is needed for at-home use?
• Side effects: what should I do if bone pain or injection site reactions occur?
• Warning signs: when should I seek urgent care for possible splenic or respiratory issues?
• Monitoring: how often will blood counts be checked during cycles?
• Alternatives: are biosimilars appropriate for my plan if availability changes?

Authoritative Sources

For detailed product information, consult these official resources:

• Manufacturer Prescribing Information
• FDA DailyMed
• Health Canada Drug Product Database

Ready to proceed? You can order securely and choose fulfilment with prompt, express shipping, and temperature-controlled handling when required. Always follow your prescriber’s directions; this page is not a substitute for medical advice.